WASHINGTON (AP) — The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Moderna (MRNA) has been struggling to shake one label for years: Covid winner. That label helped to make the company famous, but it also became a problem for the stock when pandemic demand dropped and ...
Hosted on MSN
FDA approves Moderna's first mRNA flu vaccine, marking a milestone in influenza prevention
In a landmark decision, the US Food and Drug Administration (FDA) has approved Moderna's first mRNA-based seasonal influenza vaccine. This makes it the first flu shot developed on messenger RNA (mRNA) ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On August 5, 2026, Moderna announced that the FDA approved mFLUSIVA (mRNA-1010), a new seasonal influenza vaccine, for use in all adults 50 years of age and older. As we previously reported, FDA’s ...
Moderna (MRNA) shares reached the highest level since March after the FDA issued comments that Jefferies said gave a “balanced” view on the company’s flu vaccine candidate, mRNA-1010, ahead of an ...
Moderna remains a 'Sell' as the stock prices in near-perfect execution across its late-stage pipeline and oncology ambitions. The recent FDA reversal for mRNA-1010 and a $2.25B patent settlement offer ...
Moderna stock has rallied more than 200% since August, following positive Phase 3 trial results for a melanoma vaccine.
Add Yahoo as a preferred source to see more of our stories on Google. A Moderna logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024. The Food and Drug Administration has ...
Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the ...
CAMBRIDGE, MA / ACCESS Newswire / June 18, 2026 / Moderna, Inc. (NASDAQ: MRNA) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results